Katharine Pestell

Identification of a Potent and Selective Pharmacophore for Cdc25 Dual Specificity Phosphatase Inhibitors.

John S. Lazo, Kaoru Nemoto, Katharine Pestell et al. · Molecular Pharmacology · 2002 · 182 citations

Effect of p53 Status on Sensitivity to Platinum Complexes in a Human Ovarian Cancer Cell Line

Katharine Pestell, Stephen M. Hobbs, Jenny Titley et al. · Molecular Pharmacology · 2000 · 111 citations

Characterisation of theP53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines

Katharine Pestell, Clare J. Medlow, Jenny Titley et al. · International Journal of Cancer · 1998 · 30 citations · Full text

Gynecology, Pathology, Platinum Drug Sensitivity +16

Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo

Paul A. Clarke, Katharine Pestell, Francesca Di Stefano et al. · British Journal of Cancer · 2004 · 20 citations · Full text

The antisignaling agent SC-alpha alpha delta 9, 4-(benzyl-(2-[(2,5-diphenyloxazole-4-carbonyl)amino]ethyl)carbamoyl)- 2-decanoylaminobutyric acid, is a structurally unique phospholipid analogue with phospholipase C inhibitory activity.

Andreas Vogt, Katharine Pestell, Billy W. Day et al. · PubMed · 2002 · 16 citations

Unique Phospholipid Analogue, Cell Death, Medicinal Chemistry +17